Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis - Bielekova, B; Catalfamo, M; Reichert-Scrivner, S (Proc Natl Acad Sci U S A, 2006)
et al.